By Deena Beasley

(Reuters) -Biotechnology company Amgen Inc (NASDAQ:AMGN) on Thursday said its third-quarter revenue rose 1% as higher volume growth for its cancer, rheumatology and cardiovascular products was offset by lower prices and foreign exchange losses.

Revenue for the quarter totaled $6.7 billion, exceeding Wall Street estimates of $6.56 billion, as compiled by Refinitiv.

“Our medicines generated 8% volume growth in the quarter globally, with 11 products achieving record quarterly sales,” Amgen Chief Executive Robert Bradway said in a statement.

Adjusted earnings per share increased to $4.70 from $4.08 a year earlier, beating analyst estimates of $4.42.

Net income rose 14% to $2.14 billion.

For the full year, Amgen narrowed its outlook for adjusted earnings per share to a range of $17.25 to $17.85 on revenue of $26 billion to $26.3 billion, from its previous forecast of $17 to $18 per share on revenue of $25.5 billion to $26.4 billion.

Amgen shares, which closed nearly 1.2% lower at $265.88 in regular trading, were back up 1.2% at $269 after hours.

Amgen said it will announce on Monday at the annual American Heart Association scientific meeting mid-stage trial results for experimental heart drug olpasiran, as well as an update on AMG133, a potential obesity treatment.

AMG133, which has garnered increased attention following strong sales for similar drugs launched recently by Eli Lilly (NYSE:LLY) and Co and Novo Nordisk (NYSE:NVO), is designed to block a hormone and a protein involved in blood sugar control.

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Leave a Reply

Your email address will not be published. Required fields are marked *